secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001193125-23-157992
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 3.03, 3.02, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio raises $28M via convertible preferred, cuts 2023 revenue guidance to ~$35M
--------------------------------------------------------------------------------

- Gross proceeds of $28.0M from redeemable convertible preferred; warrants could add $46.2M if cash exercised.
- 2023 revenue guidance lowered to approximately $35M; operating expenses ~$55M; gross margin 57% unchanged.
- CEO states goal to approach profitability in 2024 timeframe; financing led by Novalis LifeSciences.
- Paul Meister of Novalis appointed to board of directors, expanding board from seven to eight.
- Private placement expected to close June 2, 2023; investors include Northpond, BroadOak, and CEO affiliate M-185.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/0001193125-23-157992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000119312523157992/d514788d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-157992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer